Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cel symbols : Bmy save search
Global Merkel Cell Carcinoma Disease Treatment Market (2021 to 2026) - Featuring Merck, Pfizer and Amgen Among Others
Published: 2022-03-01 (Crawled : 21:00) - prnewswire.com
MCK | $518.81 -1.35% 0.0% 630K
|
Distribution Services
|
| O: 0.61%
H: 1.62%
C: 0.15%
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 0.19%
H: 0.71%
C: 0.13%
ONCS | $0.2772 25.59% 52M
|
Health Services
|
| O: -0.84%
H: 2.11%
C: 1.05%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: 0.0%
treatment disease cel cell carcinoma
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
Published: 2022-02-14 (Crawled : 23:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 0.27%
H: 0.2%
C: 0.0%
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: -0.01%
H: 0.22%
C: -0.09%
EXEL | $22.47 -1.75% -1.78% 2.6M
|
Health Technology
|
| O: -0.27%
H: 1.12%
C: -0.59%
opdivo renal trial cel cell carcinoma nivolumab
Bristol Myers Squibb Enters Into $5 Billion Aggregate Accelerated Share Repurchase Agreements
Published: 2022-02-09 (Crawled : 12:30) - biospace.com/
MS | News 0 d | $90.26 0.2% 0.0% 6.7M
|
Finance
|
| O: 0.78%
H: 0.0%
C: 0.0%
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: -0.68%
H: 0.0%
C: 0.0%
cel
Global Cell & Gene Therapy Market Research Report 2022: Expanding Application for Cell & Gene Therapies & Growing Demand for CAR T- Cell Therapies
Published: 2022-02-01 (Crawled : 21:00) - prnewswire.com
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: -0.53%
H: 0.21%
C: -0.07%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.95%
H: 0.0%
C: 0.0%
ema application gene therapy research cel gene therapies report therapy growing t-cell
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3B
Published: 2022-01-28 (Crawled : 13:00) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: -0.28%
H: 1.95%
C: 1.93%
cel positive therapy chmp t-cell
TCR² Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo® and Yervoy® in Mesothelin-Expressing Solid Tumors
Published: 2021-10-25 (Crawled : 11:00) - globenewswire.com
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: -0.08%
H: 0.77%
C: 0.16%
TCRR 4 | $1.48 3.38% 3.9M
|
Health Technology
|
| O: -0.88%
H: 1.92%
C: 0.88%
solid tumors collaboration trial cel
The New England Journal of Medicine Publishes Results from Pivotal Phase 2 KarMMa Study of Idecabtagene Vicleucel (Ide-cel, bb2121), an Investigational BCMA-Directed CAR T Cell Therapy
Published: 2021-02-24 (Crawled : 00:00) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 0.3%
H: 3.32%
C: 2.78%
BLUE | $0.9583 -0.52% -0.52% 6.5M
|
Health Technology
|
| O: 2.65%
H: 1.48%
C: -1.44%
phase 2 therapy results t-cell car-t cel
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.